• 1. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 2. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409
• 3. Excited-state proton-coupled electron transfer within ion pairs?
  Gerald J. Meyer,Leif Hammarstr?m Chem. Sci., 2020,11, 3460-3473
• 4. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzimidazoles Sulfinylbenzimidazoles

Comprehensive Guide to N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 (CAS No. 1794756-36-7)

N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 (CAS No. 1794756-36-7) is a deuterated analog of Lansoprazole, a well-known proton pump inhibitor (PPI). This compound is specifically designed for research purposes, particularly in pharmacokinetic and metabolic studies. The incorporation of deuterium atoms enhances its stability, making it an invaluable tool in analytical chemistry and drug development.

The molecular structure of N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 features a 2-pyridinylmethyl group substituted with a 3-methyl-4-(2,2,2-trifluoroethoxy) moiety. The presence of deuterium at four positions significantly reduces metabolic degradation, which is crucial for accurate mass spectrometry analysis. Researchers often use this compound as an internal standard in LC-MS/MS assays to quantify Lansoprazole and its metabolites in biological samples.

In recent years, the demand for deuterated compounds like N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 has surged due to advancements in precision medicine and personalized drug therapy. Pharmaceutical companies and academic institutions are increasingly focusing on stable isotope-labeled compounds to improve the reliability of drug metabolism studies. This trend aligns with the growing interest in deuterated drugs and their potential to enhance therapeutic efficacy.

One of the key applications of N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 is in the field of gastrointestinal research. Given that Lansoprazole is widely used to treat acid-related disorders such as GERD and peptic ulcers, its deuterated form plays a pivotal role in understanding drug interactions and metabolic pathways. This is particularly relevant as the global prevalence of gastrointestinal diseases continues to rise, driven by factors like stress, poor diet, and H. pylori infections.

From a technical standpoint, N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 exhibits high chemical purity and isotopic enrichment, typically exceeding 98%. These characteristics ensure minimal interference in analytical assays, making it a preferred choice for high-throughput screening and regulatory compliance testing. The compound’s stability under various pH conditions further enhances its utility in in vitro and in vivo studies.

The synthesis of N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 involves sophisticated techniques such as deuterium exchange and catalyzed hydrogenation. These methods require specialized equipment and expertise, underscoring the compound’s niche application in advanced research. As the pharmaceutical industry embraces green chemistry principles, efforts are underway to optimize the synthesis process to reduce environmental impact.

Market dynamics indicate a steady growth trajectory for deuterated compounds, with N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 being no exception. The compound is primarily supplied by specialty chemical manufacturers catering to the life sciences sector. Its pricing reflects the high cost of isotopic labeling and stringent quality control measures, but the investment is justified by the unparalleled data accuracy it delivers.

For researchers exploring the pharmacokinetics of Lansoprazole, N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 offers a robust solution. Its use extends to drug-drug interaction studies, where understanding the impact of concomitant medications on PPI metabolism is critical. This is especially pertinent given the increasing polypharmacy trends among aging populations worldwide.

In summary, N-3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinylmethyl Lansoprazole-d4 (CAS No. 1794756-36-7) is a cutting-edge research tool that bridges the gap between basic science and clinical applications. Its role in advancing precision medicine and drug development cannot be overstated, making it a subject of ongoing interest in the scientific community.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)